中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
1期
103-105
,共3页
肝性脑病%肝硬化%乳果糖%利福昔明
肝性腦病%肝硬化%乳果糖%利福昔明
간성뇌병%간경화%유과당%리복석명
Hepatic encephalopathy%Hepatocirrhosis%Lactulose%Rifaximin
目的：观察利动（66.7%乳果糖）口服溶液治疗肝硬化并发C型肝性脑病的疗效及安全性。方法根据患者的不同的经济状况及自身意愿，将肝硬化并发C型肝性脑病的住院患者78例分为治疗组（n=39）和对照组（n=39），治疗组给予利动及常规治疗，对照组予利福昔明加常规治疗。于治疗前及治疗后24h、14d按照国外广泛使用的简易肝性脑病严重程度评分表（CHESS）进行程度评定并记录不良反应。结果与治疗前相比，治疗后24h、14d两组CHESS评分均下降[治疗组：（5.8±3.1）VS（2.1±2.0），P＜0.05；对照组：（5.9±3.0）VS（3.6±2.5），P＜0.05）]，治疗组优于对照组（P＜0.05）。结论利动可明显改善肝性脑病所致的神经精神障碍，疗效优于利福昔明加常规治疗，并可改善远期预后，安全性良好。
目的：觀察利動（66.7%乳果糖）口服溶液治療肝硬化併髮C型肝性腦病的療效及安全性。方法根據患者的不同的經濟狀況及自身意願，將肝硬化併髮C型肝性腦病的住院患者78例分為治療組（n=39）和對照組（n=39），治療組給予利動及常規治療，對照組予利福昔明加常規治療。于治療前及治療後24h、14d按照國外廣汎使用的簡易肝性腦病嚴重程度評分錶（CHESS）進行程度評定併記錄不良反應。結果與治療前相比，治療後24h、14d兩組CHESS評分均下降[治療組：（5.8±3.1）VS（2.1±2.0），P＜0.05；對照組：（5.9±3.0）VS（3.6±2.5），P＜0.05）]，治療組優于對照組（P＜0.05）。結論利動可明顯改善肝性腦病所緻的神經精神障礙，療效優于利福昔明加常規治療，併可改善遠期預後，安全性良好。
목적：관찰리동（66.7%유과당）구복용액치료간경화병발C형간성뇌병적료효급안전성。방법근거환자적불동적경제상황급자신의원，장간경화병발C형간성뇌병적주원환자78례분위치료조（n=39）화대조조（n=39），치료조급여리동급상규치료，대조조여리복석명가상규치료。우치료전급치료후24h、14d안조국외엄범사용적간역간성뇌병엄중정도평분표（CHESS）진행정도평정병기록불량반응。결과여치료전상비，치료후24h、14d량조CHESS평분균하강[치료조：（5.8±3.1）VS（2.1±2.0），P＜0.05；대조조：（5.9±3.0）VS（3.6±2.5），P＜0.05）]，치료조우우대조조（P＜0.05）。결론리동가명현개선간성뇌병소치적신경정신장애，료효우우리복석명가상규치료，병가개선원기예후，안전성량호。
Objective To observe the efficacy and safety of lactulose oral solution(66.7% lactulose) in the treatment of hepatocirrhosis complicated with type C hepatic encephalopathy. Methods Seventy-eight inpatients with hepatocirrhosis complicated with type C hepatic encephalopathy were divided into the treatment group(n=39) and the control group(n=39) according to the different economic status of patients and their wishes. The patients in the treatment group were given lactulose oral solution and routine treatment, while the patients in the control group were given rifaximin and routine treatment. The degree of hepatic encephalopathy of patients were evaluated by foreign extensive use of clinical hepatic encephalopathy staging scale(CHESS) before the treatment and at 24h and 14d after the treatment, and the adverse reactions of patients were recorded. Results Compared with before the treatment, the CHESS score of two groups decreased at 24h and 14d after the treatment[(the treatment group: (5.8±3.1) VS (2.1±2.0), P < 0.05; the control group: (5.9±3.0) VS (3.6±2.5), P < 0.05], the curative effect of the treatment group was better than that of the control group(P<0.05). Conclusion Lactulose oral solution can obviously improve the neuropsychiatric disorders caused by hepatic encephalopathy, and the curative effect of lactulose oral solution is better than that of rifaximin and routine treatment, and can improve the long-term prognosis, has a good safety.
